|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2012
|
|
gptkbp:ATCCode
|
gptkb:R07AX02
|
|
gptkbp:bioavailability
|
35%
|
|
gptkbp:brand
|
gptkb:Kalydeco
|
|
gptkbp:CASNumber
|
873054-44-5
|
|
gptkbp:category
|
orphan drug
|
|
gptkbp:combines
|
gptkb:elexacaftor
gptkb:lumacaftor
gptkb:tezacaftor
|
|
gptkbp:contraindication
|
severe liver impairment
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:drugInteraction
|
CYP3A inducers
CYP3A inhibitors
|
|
gptkbp:eliminationHalfLife
|
12 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C24H28N2O3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ivacaftor
|
|
gptkbp:indication
|
gptkb:G551D_mutation_in_CFTR
other gating mutations in CFTR
|
|
gptkbp:IUPACName
|
gptkb:N-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydroquinoline-3-carboxamide
|
|
gptkbp:KEGGID
|
D09716
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
CFTR potentiator
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patent
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
99%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1237045
16220172
DB08820
17232841
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
abdominal pain
dizziness
headache
rash
upper respiratory tract infection
|
|
gptkbp:synonym
|
gptkb:VX-770
|
|
gptkbp:target
|
gptkb:CFTR_protein
|
|
gptkbp:UNII
|
6S6W9VH7F8
|
|
gptkbp:usedFor
|
cystic fibrosis
|
|
gptkbp:bfsParent
|
gptkb:VX-770
gptkb:CFTR
|
|
gptkbp:bfsLayer
|
7
|